May 11, 2016 8:30am EDT
Download as PDF
MIAMI--(BUSINESS WIRE)--
OPKO Health, Inc. (NYSE: OPK )
today announced the appointment of Douglass Laidlaw, PhD as Vice
President of Medical Affairs to support the anticipated launch of
RAYALDEE ® .
Dr. Laidlaw has over 15 years of experience in leading strategic
planning, development and execution of medical education initiatives for
numerous pharmaceutical companies, including Relypsa, Keryx, Sanofi,
Genzyme, Neurocine Biosciences, Serono and Organon. He has been involved
in new product launches targeting patients with chronic kidney disease
and has deep connections with key nephrology opinion leaders. Prior to
joining OPKO, Dr. Laidlaw served as Relypsa’s Executive Director,
Medical Affairs, and Sanofi’s National Director, Medical Science
Liaisons, Medical Affairs.
“Doug is a key addition to the management team in OPKO’s Renal
Division,” said Phillip Frost, M.D., Chairman and Chief Executive
Officer of OPKO. “A well-conceived and executed medical education
strategy is critical to Rayaldee’s acceptance by U.S. healthcare
professionals.”
About OPKO Health, Inc.
OPKO Health, Inc. is a diversified healthcare company that seeks to
establish industry-leading positions in large, rapidly growing markets.
Our diagnostics business includes Bio-Reference Laboratories, the
nation's third-largest clinical laboratory with a core genetic testing
business and a 420-person sales force to drive growth and leverage new
products, including the 4Kscore® prostate cancer test and the Claros®1
in-office immunoassay platform. Our pharmaceutical business features
Rayaldee™, a treatment for secondary hyperparathyroidism in stage 3-4
chronic kidney disease patients with vitamin D insufficiency and VARUBI™
for chemotherapy-induced nausea and vomiting (oral formulation launched
by partner Tesaro, IV formulation in Phase 3). Our biologics business
includes hGH-CTP, a once-weekly human growth hormone injection (in Phase
3 and partnered with Pfizer), a long-acting Factor VIIa drug for
hemophilia (in Phase 2a) and a long acting oxyntomodulin for diabetes
and obesity (in Phase 1). We also have production and distribution
assets worldwide, multiple strategic investments and an active business
development strategy. More information is available at www.opko.com .
View source version on businesswire.com: http://www.businesswire.com/news/home/20160511005735/en/
OPKO Health, Inc.
Investor Relations
Tara Mackay, 305-575-4100
or
Media
Rooney
& Associates
Terry Rooney, 212-223-0689
or
Marion
Janic, 212-223-4017
or
Investors
LHA
Anne
Marie Fields, 212-838-3777
or
Bruce
Voss, 310-691-7100
Source: OPKO Health, Inc.
Released May 11, 2016
email Email Alerts
location_city Company Profile
contact_page Contacts
rss_feed RSS News Feed
account_tree Sitemap
Apply on OPKO Health (Ireland)’s careers page